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Abstract 
SCOPE:  
The potential benefit of vitamin K as a therapeutic in osteoporosis is controversial and 
the vitamin K regimen treatment being used clinically (45mg/day) employs doses that 
are many times higher than those required to ensure maximal gamma-carboxylation 
of the vitamin K-dependent bone proteins. We therefore tested the hypothesis that 
vitamin K catabolites, 5-carbon (CAN5C) and 7-carbon carboxylic acid (CAN7C) 
aliphatic side-chain derivatives of the naphthoquinone moiety exert an osteotrophic 
role consistent with potential utility in the treatment of osteoporosis.  
METHODS AND RESULTS:  
Osteoblast-like MG63 cell cultures were challenged with lipopolysaccharide and the 
levels of interleukin-6, an osteoclastogenic cytokine, measured with and without 
catabolites; Low concentrations of CAN7C significantly inhibited interleukin-6 release, 
but CAN5C did not. In models of bone loss induced by ovariectomy (OVX) or sciatic 
neurectomy (SN) in C57BL/6 mice, we found that the rarer CAN7C catabolite markedly 
restricted OVX-induced bone loss and possibly limited SN–induced bone loss. CAN7C 
activity depends on a free carboxylic acid and its particular side-chain structure.  
CONCLUSION:  
These data indicate for the first time that the clinical utility of high dose vitamin K for 
osteoporosis may reside in an unusual catabolite.  
  
1. Introduction 
Vitamin K is required for the post-translational gamma-carboxylation of specific 
glutamic acid residues in several bone proteins. These observations initiated 
investigations into the potential role of vitamin K in skeletal tissue development and 
homeostasis and its use in the treatment of osteoporosis [1,2]. Clinical therapeutic use 
of vitamin K in osteoporosis has predominately been used in the Far East, and in 
particular Japan, as a high-dose regimen consisting of 45mg/day menaquinone-4; a 
vitamin K2 homologue. This dose was found clinically to be lowest effective 
therapeutic dose [3]. Although the significance of this therapeutic modality for bone 
mineral density benefit remains controversial, the reduction of fracture incidence 
supports its value as a clinical tool in the management of osteoporosis [4-6]. In 
contrast, other studies have shown no beneficial impact of vitamin K therapy on 
skeletal health [7-9] and its therapeutic value has been called into question until 
definitive investigations have been completed [10]. 
An intriguing paradox emerges, however, when the potential therapeutic mechanisms 
of high dose vitamin K are considered. It is clear, for instance, that the dose used to 
treat osteoporosis in Japan is significantly greater than is required to achieve maximal 
post-translational gamma-carboxylation of the transformable glutamyl residues in the 
bone protein osteocalcin [11]. Similarly, we have found in a cohort of mature healthy 
women that administration of 300ug vitamin K1 can reduce the levels of 
undercarboxylated osteocalcin down to those commonly found in younger adult 
women (Hodges and Soper, unpublished data). This indicates that high-dose vitamin 
K may have an alternative mechanism of action in skeletal biology that is unrelated to 
the classical biochemical function of vitamin K and gamma-carboxyglutamic acid 
formation, and suggests a novel mechanism is potentially responsible for the beneficial 
effects of high-dose vitamin K in Japanese osteoporotic patients.  
Vitamin K is subject to metabolic processing involving an initial ω-oxidation of its 
aliphatic side-chain, followed by successive β-oxidation steps to generate short 
branch-chained aliphatic carboxylic acid side-chain at position 3 of the 
naphthoquinone [12-15]. This area has been recently been the subject of a thorough 
review by Harrington and colleagues [16]. 
Nutritional vitamin K intake metabolism produces mostly a 5-carbon, branched side-
chain, aliphatic carboxylic acid at position 3 on the 2-methyl-1,4-naphthoquinone 
moiety (CAN5C) and notably lesser amounts of a 7-carbon aliphatic carboxylic acid 
homologue (CAN7C) (Fig. 1) [12-14]. Levels of CAN7C are substantially increased, 
however, following pharmacological doses of vitamin K1 or K2 [14]. These data have 
led us to hypothesize that vitamin K catabolites, namely CAN5C and CAN7C, exert 
actions in bone and provide an alternative mechanism of action for high-dose vitamin 
K therapy. We explored this hypothesis by examining whether these vitamin K 
catabolites can modify agonist-induced production of interleukin-6 (IL-6), a known 
osteoclastogenic cytokine implicated in the pathophysiology of osteoporosis [17-20], 
in osteoblast-like cells (MG63) in vitro and by determining their in vivo effects in two 
recognised murine models of bone loss induced by either ovariectomy or neurectomy. 
Our studies indicate that the CAN7C catabolite of vitamin K suppresses IL-6 
production by osteoblast-like cells in vitro and exerts a protective role against 
ovariectomy-induced bone loss. 
 
2. Materials and Methods 
 
Naphthoquinone Compound Syntheses 
The natural CAN5C, CAN7C catabolites of vitamin K and a novel straight chain 8-
carbon aliphatic carboxylic acid 2-methyl-1,4-naphthoquinone compound (CAN8C; a 
more hydrophobic homologue not found in nature) as well as the methyl ester form of 
each (CAN5C-Me, CAN7C-Me and CAN8C-Me), (Fig. 1) were synthesized using 
standard chemical procedures. All chemicals and materials were purchased from 
Sigma Aldrich, Dorset, UK unless otherwise stated. 
Synthesis involved joining respective side-chains to a cyclopentadiene-
naphthoquinone adduct, formed by a Diels-Alder reaction. A retro Diels-Alder reaction 
was used to produce the methyl esters, which were subsequently each enzymatically 
hydrolysed to yield the corresponding carboxylic acids.  
The side chain for CAN7C was produced through a multistep synthesis. Briefly, the 
alcohol group of 3-methylbut-2-ene-1-ol was protected with Tert-
butyldimethylsilylchloride, then meta-chloroperoxybenzoic acid was used to epoxidate 
this protected alcohol, the resultant tert-butyl-(3,3-
dimethyloxiranylmethoxy)dimethylsilane was subsequently converted to tert-
butyldimethyl-(2-hydroxy-3-methylbut-3-enyloxy)silane by regioselective thermal 
rearrangement. Production of (E)-methyl 6-(tert-butyldimethylsilanyloxy)-4-methylhex-
4-enoate was achieved by a Claisen rearrangement using trimethylorthoacetate and 
proprionic acid. The tert-butyldimethylsilane group was then cleaved from the ester 
using tetrabutylammonium fluoride to yield the alcohol. The final bromination step in 
the side-chain synthesis was performed using carbon tetrabromide and 
triphenylphosphine to yield (E)-Methyl 6-bromo-4-methylhex-4-enoate. 
The synthesis of the 5-carbon carboxylic acid side chain was initiated by the 
production of methyl-4-bromo-2(R,S)-methylbutanoate from 2(R,S)-methyl-4-
butyrolactone using phosphorus tribromide and methanol. The resultant bromide was 
converted into methyl-4-iodo-2(R,S)-methylbutanoate by a Finkelstein reaction using 
sodium iodide in dry acetone. The 8-carbon carboxylic acid side-chain was 
synthesised using essentially the same method except that 8-bromooctanoic acid as 
the starting material.  
Each of these compounds was purified by sequential column chromatography and 
their authenticities and purities verified by NMR spectroscopy on a Jeol EX 270MHz 
spectrometer and mass spectra obtained using VG Biotech Quattrol 2 instrument and 
confirmed by HPLC with electrochemical detection. The compounds used in all 
experiments were >98% pure. 
 
Osteoblast Cell Culture 
Human osteosarcoma-derived osteoblast-like MG63 cells (American Type Culture 
Collection), were cultured at a seeding density of 200,000 in 24 well plates (Nunc) in 
Dubellco’s minimum essential medium (DMEM) (Gibco) supplemented with 10% fetal 
calf serum (FCS) (Hyclone), L-glutamine (4mM) (Gibco), penicillin (200 units/ml) and 
streptomycin (200g/ml) (Gibco) at 37oC in a humidified atmosphere of 5% CO2, until 
they achieved 80-85% confluence. At this point, the cell growth cycles were 
synchronised in DMEM lacking FCS for 24 hours and then cultured in DMEM 
containing 2% FCS for a further 24 hours. Medium was then replaced with fresh DMEM 
supplemented with 2% FCS as a negative control or the cultures were challenged with 
bacterial lipopolysaccharide (LPS). LPS or surface associated material (SAM) from 
several bacterial species were examined for the ability to release IL-6 from cultured 
MG63 cells before selection of Escherichia coli serotypes 0111:B4 (25ng/ml: 50% 
maximal IL-6 stimulation concentration) for the positive control. Media were further 
supplemented with each of the vitamin K catabolites (CAN5C, CAN7C or CAN8C or 
their respective methyl esters) at between 10-8 to 10-5 M in the presence of LPS 
(25ng/ml). The vitamin K catabolites were soluble in ethanol and final ethanol 
concentration was 2%; the negative and positive controls also contained 2% ethanol. 
The cells were then incubated for a further 24 hours. After this time the media was 
aspirated and stored at –80oC until analysed by ELISA for the osteoclastogenic 
cytokine IL-6.  
 
ELISA Assay 
An in-house ELISA assay was developed [21], briefly, Nunc Maxisorp 96-well plates 
were coated with 100l/well of anti-IL-6 coating antibody at (1g/ml) in standard assay 
diluent (PBS) and stored overnight at 4oC. All antibodies and conjugated streptavidin-
horseradish peroxidase were purchased from Biosource, SARL, Belgium. The plates 
were blocked with 300l/well of standard assay diluent containing 5g/L bovine serum 
albumin (Fraction V) and left for 2 hours at room temperature. The plates were then 
washed with PBS containing 0.1% Tween 20 v/v, followed by the addition of diluted 
standards or samples. Immediately following this biotinylated IL-6 detection antibody 
(0.4g/ml) in standard assay diluent containing 5g/L bovine serum albumin was added 
and the plates left to stand for 2 hours at room temperature. The plates were then 
washed before the addition of streptavidin-horseradish peroxidase in standard assay 
diluent containing 5g/L bovine serum albumin and the plate left to incubate for 20 
minutes at room temperature. After washing the plates o-phenylenediamine in 
substrate buffer (0.05M phosphate-citrate buffer (pH 5.0) containing 0.03% sodium 
perborate) was added. The reaction was stopped by the addition of 1 M sulphuric acid 
and the plates were read at 450nm, referenced at 630nm.  
 Proliferation Assay 
The effects of the vitamin K catabolites on osteoblast proliferation were examined 
using the cell culture procedure described above. After synchronisation of cell growth 
cycles, MG63 cells  were cultured in DMEM containing 2% FCS for 18 hours with and 
without LPS (E. coli serotype 0111:B4), and with or without supplementation with each 
of the vitamin K catabolites,  before addition of 3H-thymidine in DMEM (0.37MBq/ml) 
to all the wells for a further 6 hours. Media were removed, cells washed with PBS and 
the plates freeze-thawed in PBS containing 1% Tween-20. The cell lysate was 
aspirated through a printed filter-mat using a cell harvester and radioactivity (cpm) 
measured on a scintillation counter.  
 
Animal Studies 
Ovariectomy model 
Female C57BL/6 mice were obtained from Charles Rivers at 8 weeks age and housed 
under standard conditions according to local and UK Home Office regulations. All 
experiments were done under Home Office licence and local, Royal Veterinary 
College, ethical regulations governing animal experimentation.  
After acclimatization in 12hr dark / light conditions in groups of 4 for 2 weeks the 
animals were randomly assigned to, sham-operated, ovariectomized and 
ovariectomized-treated [22]. The day after surgery animals received 15µg of freshly 
prepared naphthoquinone compounds (CAN7C and CAN8C or their respective methyl 
esters) per day (ethanol/saline 2% v/v solution) by intraperitoneal injection. A higher 
dose of 30µg CAN7C was also investigated in a group of ovariectomized mice. 
Controls received ethanol/saline (2% v/v) solution daily. The animals were presented 
ad libitum water and standard chow and weighed daily. After 5 weeks the mice were 
sacrificed and the right tibiae removed, cleaned of soft tissues and prepared for micro-
computerized tomography analyses.  
 
Neurectomy model 
Following evaluation of the results from the ovariectomy studies, only CAN7C was 
used to evaluate effects on neurectomy-induced bone loss. Female C57BL/6 mice, 
housed as described above. Using methods previously described [23] all mice had the 
right sciatic nerve severed and a 2mm section removed, thereafter mice were 
randomly assigned to one of three groups; control untreated and two treatment groups. 
The day after surgery the treated animals received either 15 or 30µg of freshly made 
CAN7C per day by intraperitoneally in an ethanol/saline (2% v/v) solution. The 
untreated animals received an ethanol/saline (2% v/v) vehicle solution daily. Two 
weeks after surgery the animals were sacrificed and both tibiae removed cleaned of 
soft tissues and prepared for micro-computed tomography analyses.  
 
Micro-Computed Tomography Analysis 
Right tibiae from ovariectomized mice and both tibiae from neurectomized mice were 
dissected, fixed in 10% neutral buffered formalin for 48 h, rinsed in tap water for 3 h 
and stored in 70% ethanol. The tibiae were briefly rehydrated in physiological saline 
(0.09%) prior to being scanned using a micro-computed tomography (mCT) system 
(Skyscan 1172 X-Ray Microtomograph, Aartselaar, Belgium) to evaluate trabecular 
architecture and geometry using methods described by us elsewhere [23]. Briefly, 
high-resolution scans with an isotropic voxel size of 5 m were acquired (scan time 
approximately 1 h 30 min for each bone), then reconstructed using NRecon (Skyscan) 
and analysed using CTAn (Skyscan). In the trabecular bone compartment, bone 
volume to total volume ratio (BV/TV), trabecular number (Tb.N; /mm), trabecular 
thickness (Tb.Th; mm), trabecular separation (Tb.Sp), were evaluated. Coefficients of 
variation for these parameters were within empirical tolerance for this technique: 
BV/TV=1.65%; Tb.No.: 1.72%; Tb.Tk: 0.85%; Tb.Sp: 0.85%. 
 
Statistical Analyses 
The data were initially examined for normality of distribution and equal variance. The 
in vitro cell culture data were found to be normally distributed and had equal variances 
within each experiment. These results were analysed by one-way ANOVA followed by 
a Bonferroni multiple comparison tests. The in vivo data required non-parametric 
analyses due to failing to meet normality tests, which could not be normalized by log 
transformation. Therefore Kruskal-Wallis one-way ANOVA test were done followed by 
Dunn’s multiple comparison test. All analyses were done using GraphPad Prism 6.0 
statistical package and the results are shown in Table 1 (GraphPad Software, Inc., La 
Jolla, CA).  
 
3. Results 
The vitamin K catabolite, CAN7C inhibits in vitro IL-6 release from osteoblasts 
The osteoblast-like cell line MG63 produces IL-6 when challenged with LPS, the 
responses were found to be variable between batches of LPS and the most 
reproducible results were obtained with Escherichia coli serotype 0111:B4. Six 
naphthoquinone compounds (CAN5/7/8C and their methyl esters) were tested for their 
capacity to inhibit IL-6 release from LPS-challenged MG63 cells, several experiments 
were done for each compound and representative results are shown in Fig. 2. It is 
interesting to observe that the two most closely related compounds CAN5C and 
CAN7C consistently had substantially different activities with respect to their inhibition 
of IL-6 release from LPS-challenged MG63 cells; the former being less active. We also 
found that these inhibitory activities were considerably blunted in experiments using 
the corresponding methyl ester naphthoquinone compounds. There was an inhibitory 
activity of the octyl carboxylic acid naphthoquinone, which is less pronounced that that 
seen with CAN7C and appears to be enhanced in this assay by the methyl ester form 
of this compound. Clearly reduced production of IL-6 could result from a general 
cytotoxic reaction to the naphthoquinone compounds, however, the proliferation 
assays demonstrated that the compounds had no detectable cytotoxic activity up to 
10-5 M (data not shown). Incubation of MG63 cells with the individual naphthoquinone 
compounds over the described concentration range, in the absence of LPS, did not 
cause the release of IL-6 (data not shown).  
These in vitro results led to the selection of CAN7C, its methyl ester, and the equivalent 
pairing of the octyl carboxylic acid naphthoquinone compound (CAN8C) and its methyl 
ester to investigate their potential for protecting against the induced bone loss in the 
in vivo ovariectomy model. 
 
Vitamin K catabolite CAN7C inhibits murine bone loss induced by ovariectomy  
None of the animals showed overt signs of deleterious effects from the administration 
of the naphthoquinone compounds or the vehicle control solutions and all the mice 
went through to the completion of the experiments. Adopting the suggestion of 
Bouxsein, et al. [25] the four prominent architectural trabecular parameters derived 
from the micro-computed tomography analyses are presented in Fig. 3 from the OVX-
induced bone loss experiments with CAN7C compared to controls. The calculated 
probabilities for the differences between sham-operated and ovariectomized mice 
(Table 1) reveals that untreated ovariectomized mice exhibited statistically significant 
cancellous bone loss, as witnessed by the reduction in percentage bone volume in the 
total trabecular compartment. Treatment with CAN7C causes the cancellous bone in 
the tibiae in the treated mice to be statistically indistinguishable from that in the sham 
operated animals (Table 1). There was attenuation of the ovariectomy-induced bone 
loss following treatment with CAN7C at both 15 and 30 µg/day (Table 1; Fig. 3). 
Consistent with our in vitro data, methylation of the carboxylic acid greatly limits the 
protection from ovariectomy-induced cancellous bone loss observed by their free 
carboxylic acid homologues. Additionally, making the side-chain more hydrophobic, 
as in the synthetic octylcarboxylic acid naphthoquinone compound (CAN8C) and its 
methyl derivative did not produce any notable protective action (Table 1).  
 
Vitamin K catabolite CAN7C restricts sciatic neurectomy-induced bone loss 
Sciatic neurectomy produces a more intense bone loss than ovariectomy [26]. This is 
evident in our experiments as the marked difference in BV/TV, Tb No. and Tb Th 
between operated and unoperated limbs (Table 1). Comparison of BV/TV in the un-
operated limbs of untreated and treated groups indicates that these vitamin K 
derivatives failed to significantly modify basal bone architecture and mass, suggestive 
of limited change in bone turnover in these otherwise normal tibiae (data not shown). 
Comparisons between the operated, disused, limbs of the untreated and treated 
groups indicate potential amelioration of bone loss in the neurectomized limbs by 
15ug/day administration of CAN7C although this did not reach levels of statistical 
significance, while the higher dose of 30ug/day showed no potential to limit bone loss.  
 
4. Discussion 
Our findings indicate that vitamin K catabolites are effective in restricting LPS-induced 
IL-6 production by osteoblast-like cells in vitro and in reducing ovariectomy-induced 
bone loss in vivo. We find that these effects are relatively limited to the CAN7C 
derivative and these data suggest an alternative mechanism by which vitamin K may 
exert osteotrophic effects. Use of high dose vitamin K as a therapeutic for osteoporosis 
was found to be optimal at 45mg/day [3] and it has also been suggested that this 
regimen may be more beneficial in patients who are actively experiencing increased 
bone turnover [27], which would more accurately parallel our ovariectomy model. 
While 300µg/day vitamin K, a supra-normal nutritional quantity, is sufficient to gamma-
carboxylate the vitamin K-dependent bone protein osteocalcin, it does question if the 
remaining 44.7mg (99.3%) of the therapeutic 45mg/day human vitamin K dose may 
contribute to other biological functions. Our findings are consistent with the hypothesis 
that this may be due, at least in part, to the production of elevated levels of vitamin K 
catabolites in this high-dose regimen [14].  
These studies demonstrate that a catabolite of vitamin K, CAN7C, which is not 
normally found in appreciable quantities, but which shows increased levels with 
pharmaceutical doses [14], has substantial osteotrophic activity. This compound 
inhibits IL-6 release from challenged MG63 osteoblast-like cells supporting our earlier 
finding of the inhibition of this inflammatory cytokine from challenged cultured primary 
human gingival fibroblasts [28]. While IL-6 is only one of many factors that can induce 
osteoclastogenesis, the observation in distinct cell populations may implicate a 
common, undisclosed, mechanism in activated cells.  
With a normal diet, most of vitamin K is shuttled through to CAN5C [12-14]. However, 
except in high concentrations, we found that CAN5C has little inhibitory activity on IL-
6 release in the challenged MG63 culture experiments. Thus, catabolism of native 
vitamin K predominantly into the relatively inert CAN5C catabolite may therefore act 
to conserve any non-pathological IL-6 cytokine production that is part of the control of 
normal bone turnover. The observation of substantial in vitro activity difference 
between CAN5C and CAN7C, which only differ by two additional carbon atoms and a 
double bond, remains enigmatic as the increased hydrophobicity of CAN8C does not 
confer greater activity over CAN7C, suggesting that this small structural feature is 
likely to have profound biologically relevance. Furthermore, the IL-6 inhibitory action 
of CAN7C appears to require a free carboxylic acid group for full function.  
IL-6 has previously been suggested to have a role in the progression to presenting 
with osteoporosis [17-20]. It is possible that senescence-regulated DNA damage leads 
to a local inflammatory response operating through IL-6, TNF-α, RANKL etc., which 
activates the NFκβ pathway [29]. It was therefore considered appropriate to undertake 
provisional investigations of CAN7C and CAN8C for their ability to inhibit ovariectomy- 
and neurectomy-induced bone loss. Inhibition of this pathway has been noted for other 
1,4-naphthoquinone natural products, notably plumbagin, where significant 
attenuation of osteoclastogenesis through IkappaB kinase (IKK) signalling has been 
demonstrated [30]. The role of IKK in ovariectomy-induced bone loss is emerging [31], 
however, there is a paucity of published information concerning IKK in neurectomy-
induced bone loss. 
In addition to CAN7C showing an inhibition of the bone loss in the ovariectomized 
mouse (Fig. 3) we also noted that, as with the osteoblast in vitro observations, a free 
carboxylic acid moiety is required for the molecules to be fully functional and that a 
branched-chain substituent at position 3 on the naphthoquinone is more important 
than a hydrophobic straight chain aliphatic carbon structure (Table 1). It is possible 
that the residual actions of the methyl esters could be due to an esterase cleavage of 
the molecules to reveal the free acid compounds. 
It is well established that neurectomy-induced disuse produces a dramatic loss of 
cancellous bone and this is consistent with our data comparing right tibiae to their 
respective contralateral control, non-operated limb (Table 1). Our data reveal that 
15µg/day CAN7C exerts some limited impact on the neurectomy-induced bone loss 
which, although not reaching levels of statistical significance for BV/TV (p=0.14; Table 
1) may suggest potential activity in this model where bone formation may be of greater 
relevance. Interestingly, the higher dose of 30 µg/day CAN7C appears to be 
completely ineffective in this model. Both of these models of induced bone loss are 
associated with increased bone turnover and diminished bone mass, with 
ovariectomy-induced bone loss showing a higher propensity to bone resorption, 
relative to bone formation, [32-34], while neurectomy-induced bone loss shows a 
decreased bone formation rate with respect to bone resorption [26,35]. 
Administration of high dose menaquinone-4, a form of vitamin K, (50mg/Kg/day) has 
previously been shown to suppress elevated levels of osteoclast-mediated resorption 
without modifying increased osteoblast function in ovariectomized rodents [36]. In 
another study, again using menaquinone-4 (30mg/Kg/day; 3x week), in sciatic 
neurectomized rats, Iwamoto and colleagues found an attenuation of neurectomy-
induced cancellous bone loss and increased bone formation rate [37]. As rats can 
break down vitamin K into carboxylic acid catabolites [38], it is, of course, possible that 
this attenuation of cancellous bone turnover is due to increased endogenous 
production of CAN7C. 
The results presented here also need to be viewed in a broader context. The potential 
to deliver a consistent supply of the CAN7C from the administration of high doses of 
vitamin K will be subject to several variables; including taking vitamin K with food to 
aid gut absorption, compliance and other factors such as liver function. With specific 
reference to liver function, hepatectomy of the rat has shown that it is the dominant 
organ for vitamin K storage, catabolism and excretion [39-41]. Ageing is associated 
with decreasing general hepatic function [42] and a decreasing ability to metabolise 
xenobiotic molecules [43]. Although vitamin K metabolism has not been specifically 
addressed in an older human cohort, the new-born infant has been shown by 
Harrington and colleagues [44] to have some degree of impaired hepatic vitamin K 
catabolic activity; reflected as a greater CAN7C production following a pharmaceutical 
dose. Equally, if catabolism of vitamin K can occur in other tissues the molecular 
architecture for this capability remains to be disclosed, which, should the enzymes be 
found in extra-hepatic tissues, bone is an interesting candidate organ as it is a rich 
depository for vitamin K [45]. Finally, as CAN7C is broken down into the relatively inert 
CAN5C or excreted directly [12-14,39], it presents an interesting molecule to consider 
from a safety perspective for the therapeutic modulation of osteopenia and 
osteoporosis. 
In conclusion, this pilot study highlights a possible role for a specific vitamin K 
catabolite in the regulation of bone metabolism. This catabolite is only appreciably 
encountered when high doses of vitamin K are administered,. This remains to be 
vigorously investigated through the use of a broader range of CAN7C doses, different 
models, longer duration of the models, larger group sizes coupled to 
pharmacodynamics, pharmacokinetic and mechanistic investigations. 
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Legends to Table and Figures: 
 
 
Table 1. The calculated probabilities for differences between the control and treated 
groups of four tibial architectural trabecular parameters measured by micro-computed 
tomography. The upper panel shows results for comparisons between sham-operated 
ovariectomized mice and the treated ovariectomized mice and the lower panel for the 
experiments with sciaticectomized mice. The statistical analyses were done using 
Kruskal-Wallis one-way ANOVA with Dunn’s multiple comparison tests.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ovariectomy BV/TV Tb Sep Tb No. Tb Th
Sham  vs Ovx 0.04 0.32 0.26 0.99
Sham  vs Ovx +15ug CAN7C 0.99 0.99 0.99 0.48
Sham  vs Ovx +30ug CAN7C 0.99 0.83 0.99 0.06
Sham  vs Ovx +15ug CAN7C Me 0.01 0.08 0.11 0.23
Sham  vs Ovx +15ug CAN8C 0.02 0.24 0.02 0.23
Sham  vs Ovx +15ug CAN8C Me 0.41 0.55 0.54 0.99
Neurectomy
Untreated operated vs unoperated tibiae <0.001 0.23 0.001 <0.001
Ratio operated to unoperated limbs
Untreated  vs 15ug CAN7C 0.14 0.99 0.21 0.99
Untreated  vs 30ug CAN7C 0.99 0.99 0.99 0.99
Calculated Probabilities
Figure 1. Naphthoquinone compounds used to investigated the potential role of this class of molecules 
in bone biology; A) the principal 5-carbon carboxylic acid natural metabolite of vitamin K (R=H); B) the 
less abundant 7-carbon carboxylic acid natural metabolite of vitamin K (R=H); C) a synthetic octyl 
aliphatic 2-methyl-1,4-naphthoquinone carboxylic acid not found in nature. The methyl esters of these 
compounds are not found naturally. 
 
 
Figure 2. Individual representative results from interleukin-6 release from cultured MG63 osteoblast-
like cells (pg/ml) challenged with E. coli lipopolysaccharide (25ng/ml: +LPS) and by LPS in the presence 
of the naphthoquinone compounds or without LPS or compound lipopolysaccharide control (-LPS) 
(mean + s.d. for 4 replicates); A) the 5-carbon carboxylic metabolite of vitamin K (CAN5C); B) the methyl 
ester of the 5-carbon carboxylic metabolite (CAN5CMe); C) the 7-carbon carboxylic metabolite of 
vitamin K (CAN7C); D) the methyl ester of the 7-carbon carboxylic metabolite (CAN7CMe); E) the 
aliphatic octyl carboxylic acid naphthoquinone (CAN8C); F) the methyl ester of the octyl carboxylic acid 
naphthoquinone (CAN8CMe): * P<0.05; ** P<0.005; *** P<0.001 all compound data was compared 
against the positive (+LPS) control. 
 
 
Figure 3. The four principle architectural parameters from micro-computerized tomography 
measurements of mice tibae after sham operation or ovariectomy, with or without naphthoquinone 
administration. Two of the ovariectomy groups were administered the 7-carbon carboxylic acid 
catabolite (CAN7C) of vitamin K at 15 or 30ug / day. Data are plotted as box and whisker plots with 
maximum and minimum extremes on discontinuous y-axes; * P<0.05 compared to sham operated mice. 
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